Soluble interleukin-2 receptor as an indicator of immunological disturbance found in silicosis patients.
Silicosis patients (SILs) possess not only respiratory disorders but also alterations in autoimmunity. To determine an early indicator of immunological disturbance in SILs, the role of serum-soluble interleukin (IL)-2 receptor (sIL-2R) was analyzed. Of ten SILs, immunological clinical parameters such as immunoglobulin (Ig) G, complements, the titer of autoantibodies including anti-nuclear antibodies (ANA), anti-Scl-70 antibody (Ab) and anti-centromere (CM) Ab, and experimental indicators such as serum-soluble Fas, serum IL-2, CD25+ cells in CD4+ or CD8+ fractions, and sIL-2R were divided from respiratory parameters such as percent vital capacity (%VC), percentage of forced expiratory volume in 1 second (FEV1.0%) and v25/Ht (liter/second/m(body height) by a correlation assay. Additionally, a stepwise regression test showed that sIL-2R was correlated with Ig G, ANA and anti-CM Ab. Furthermore, factor analysis revealed that sIL-2R contributed to the subpopulation of SILs with poorer immunological status in the absence of alterations in respiratory status. By defining healthy donors as 1, SILs as 2 and patients with systemic sclerosis as 3 for immunopathological progression status as metric variables, sIL2R and ANA showed a strong positive correlation. This suggests that sIL-2R is a good clinical indicator of immunological disturbance found in SILs without clinical manifestations of any disturbance in autoimmunity. Further analysis using a large-scale number of patients should be performed to confirm these findings.
Hayashi
H
H
Department of Hygiene, Kawasaki Medical School, Kurashiki, Japan.
Maeda
M
M
Murakami
S
S
Kumagai
N
N
Chen
Y
Y
Hatayama
T
T
Katoh
M
M
Miyahara
N
N
Yamamoto
S
S
Yoshida
Y
Y
Nishimura
Y
Y
Kusaka
M
M
Fujimoto
W
W
Otsuki
T
T
D000328:Adult; D000368:Aged; D015415:Biomarkers; D001782:Blood Donors; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D007376:Interleukin-2 / Q000097:blood; D008297:Male; D008875:Middle Aged; D015375:Receptors, Interleukin-2 / Q000097:blood*; D012595:Scleroderma, Systemic / Q000276:immunology; D012829:Silicosis / Q000276:immunology* / Q000503:physiopathology
D015415:Biomarkers; D007376:Interleukin-2; D015375:Receptors, Interleukin-2